Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
Sponsor: Memorial Sloan Kettering Cancer Center · NCT06129903 on ClinicalTrials.gov ↗
Conditions studied
What it tests
- referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.other
Where it's running8 sites
- Recruiting now
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey 07920
- Meredith Bartelstein, MD(contact)212-639-8684
- Recruiting now
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey 07748
- Meredith Bartelstein, MD(contact)212-639-8684
- Recruiting now
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey 07645
- Meredith Bartelstein, MD(contact)212-639-8684
- Recruiting now
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )
Commack, New York 11725
- Meredith Bartelstein, MD(contact)212-639-8684
- Recruiting now
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York 10604
- Meredith Bartelstein, MD(contact)212-639-8684
- Recruiting now
Memorial Sloan Kettering Cancer Center (All protocol activites)
New York, New York 10065
- Meredeith Bartelstein, MD(contact)212-639-8684
- Recruiting now
Memorial Sloan Kettering Nassau (All protocol activities)
Uniondale, New York 11553
- Meredith Bartelstein, MD(contact)212-639-8684
- Opening soon
William Beaumont Army Medical Center
Fort Bliss, Texas 79918
- Elizabeth M Polfer, MD(contact)915-742-5169
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * Age ≥18 years * Tissue diagnosis of primary bone or soft tissue sarcoma o Note: high suspicion of sarcoma on history and imaging acceptable, if reviewed and approved by the PI * Presenting to the Orthopaedic Surgery Service * Treatment plan includes surgery at MSK for treatment of the primary sarcoma * No previous treatment for sarcoma * Proficient in English * As determined by use of the Census-LEP question * The patient's response to the question: "How well do you speak English?" must be "very-well" for inclusion. Additionally, English must be identified as the patient's preferred language for discussing healthcare. Exclusion Criteria: * Significant psychiatric disturbance determined from self-report and/or chart review, sufficient, in the investigator's judgment, to preclude participation in the study" (e.g., underlying severe mental illness, h/o suicide attempts, or h/o psychiatric admissions) Clinical concern at the time of randomization of mental health urgency or emergency requiring evaluation; urgency and emergency will be defined as moderate or high scores, respectively, on the CSSR-S or according to the judgment of the orthopaedic physician evaluating the patient * Note: investigators considered exclusion of patients with no or mild symptoms of anxiety and depression, however due to risk of new symptoms arising during the course of treatment, risk of underreporting, risk of under detection, and given prior data on the high prevalence of symptoms, we elected to include all patients in this pilot study.
Updated 2026-05-15 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.